{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:51:39Z","timestamp":1792547499025,"version":"4.5.0"},"reference-count":149,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health","award":["PNRR-MAD-2022-12376632"],"award-info":[{"award-number":["PNRR-MAD-2022-12376632"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Serum biomarkers represent a reproducible, sensitive, minimally invasive and inexpensive method to explore possible adverse cardiovascular effects of antineoplastic treatments. They are useful tools in risk stratification, the early detection of cardiotoxicity and the follow-up and prognostic assessment of cancer patients. In this literature review, we aim at describing the current state of knowledge on the meaning and the usefulness of cardiovascular biomarkers in patients with cancer; analyzing the intricate relationship between cancer and cardiovascular disease (especially HF) and how this affects cardiovascular and tumor biomarkers; exploring the role of cardiovascular biomarkers in the risk stratification and in the identification of chemotherapy-induced cardiotoxicity; and providing a summary of the novel potential biomarkers in this clinical setting.<\/jats:p>","DOI":"10.3390\/biom14020199","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T06:12:58Z","timestamp":1707286378000},"page":"199","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Cardiovascular Biomarkers in Cardio-Oncology: Antineoplastic Drug Cardiotoxicity and Beyond"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3438-1537","authenticated-orcid":false,"given":"Umberto","family":"Attanasio","sequence":"first","affiliation":[{"name":"Department of Translational Medical Sciences, Federico II University, Via Sergio Pansini 5, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Di Sarro","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, Federico II University, Via Sergio Pansini 5, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4461-1885","authenticated-orcid":false,"given":"Lucia","family":"Tricarico","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Department of Medical and Surgical Sciences, University of Foggia, Viale Pinto 1, 71122 Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4510-6805","authenticated-orcid":false,"given":"Daniela","family":"Di Lisi","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy"},{"name":"Division of Cardiology, University Hospital Paolo Giaccone, Via del Vespro 129, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9775-9715","authenticated-orcid":false,"given":"Giuseppe","family":"Armentaro","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University Magna Gr\u00e6cia of Catanzaro, Campus Universitario di Germaneto, V.le Europa, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Miceli","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University Magna Gr\u00e6cia of Catanzaro, Campus Universitario di Germaneto, V.le Europa, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7174-8604","authenticated-orcid":false,"given":"Francesco","family":"Fioretti","sequence":"additional","affiliation":[{"name":"Cardiology Section, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Spedali Civili Hospital and University of Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3725-7614","authenticated-orcid":false,"given":"Martino","family":"Deidda","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari, 09042 Monserrato, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7863-253X","authenticated-orcid":false,"given":"Michele","family":"Correale","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Department of Medical and Surgical Sciences, University of Foggia, Viale Pinto 1, 71122 Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Novo","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy"},{"name":"Division of Cardiology, University Hospital Paolo Giaccone, Via del Vespro 129, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Sciacqua","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University Magna Gr\u00e6cia of Catanzaro, Campus Universitario di Germaneto, V.le Europa, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6650-1735","authenticated-orcid":false,"given":"Savina","family":"Nodari","sequence":"additional","affiliation":[{"name":"Cardiology Section, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Spedali Civili Hospital and University of Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2823-1797","authenticated-orcid":false,"given":"Christian","family":"Cadeddu","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari, 09042 Monserrato, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5983-688X","authenticated-orcid":false,"given":"Carlo Gabriele","family":"Tocchetti","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, Federico II University, Via Sergio Pansini 5, 80131 Naples, Italy"},{"name":"Interdepartmental Center of Clinical and Translational Sciences (CIRCET), Federico II University, Via Sergio Pansini 5, 80131 Naples, Italy"},{"name":"Interdepartmental Hypertension Research Center (CIRIAPA), Federico II University, Via Sergio Pansini 5, 80131 Naples, Italy"},{"name":"Center for Basic and Clinical Immunology Research (CISI), Federico II University, Via Sergio Pansini 5, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6235-984X","authenticated-orcid":false,"given":"Alberto","family":"Palazzuoli","sequence":"additional","affiliation":[{"name":"Cardiovascular Diseases Unit, Cardio-thoracic and Vascular Department Le Scotte Hospital, University of Siena, Strada delle Scotte 14, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Mercurio","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, Federico II University, Via Sergio Pansini 5, 80131 Naples, Italy"},{"name":"Interdepartmental Center of Clinical and Translational Sciences (CIRCET), Federico II University, Via Sergio Pansini 5, 80131 Naples, Italy"},{"name":"Interdepartmental Hypertension Research Center (CIRIAPA), Federico II University, Via Sergio Pansini 5, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3389\/fcvm.2019.00187","article-title":"Preventive Cardio-Oncology: The Time Has Come","volume":"6","author":"Brown","year":"2020","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"936654","DOI":"10.3389\/fcvm.2022.936654","article-title":"Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers","volume":"9","author":"Chianca","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(19)31674-5","article-title":"Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: A population-based cohort study using multiple linked UK electronic health records databases","volume":"394","author":"Strongman","year":"2019","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11936-018-0641-z","article-title":"Role of Biomarkers in Prediction of Cardiotoxicity During Cancer Treatment","volume":"20","author":"Tan","year":"2018","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s10741-021-10151-4","article-title":"Subclinical cardiac damage in cancer patients before chemotherapy","volume":"27","author":"Fabiani","year":"2022","journal-title":"Heart Fail. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Sorodoc, V., Sirbu, O., Lionte, C., Haliga, R.E., Stoica, A., Ceasovschih, A., Petris, O.R., Constantin, M., Costache, I.I., and Petris, A.O. (2022). The Value of Troponin as a Biomarker of Chemotherapy-Induced Cardiotoxicity. Life, 12.","DOI":"10.3390\/life12081183"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1161\/CIRCULATIONAHA.104.482570","article-title":"Biomarkers of Cardiovascular Disease","volume":"113","author":"Vasan","year":"2006","journal-title":"Circulation"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e12277","DOI":"10.1097\/MD.0000000000012277","article-title":"Midregional pro-atrial natriuretic peptide is a superior biomarker to N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure patients with preserved ejection fraction","volume":"97","author":"Cui","year":"2018","journal-title":"Medicine"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S0195-668X(03)00476-7","article-title":"Clinical applications of B-type natriuretic peptide (BNP) testing","volume":"24","author":"Cowie","year":"2003","journal-title":"Eur. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1016\/j.bbadis.2012.12.014","article-title":"Biomarkers and diagnostics in heart failure","volume":"1832","author":"Gaggin","year":"2013","journal-title":"Biochim. Biophys. Acta-Mol. Basis Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ijcard.2014.08.007","article-title":"Obesity and natriuretic peptides, BNP and NT-proBNP: Mechanisms and diagnostic implications for heart failure","volume":"176","author":"Madamanchi","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1373\/clinchem.2006.069575","article-title":"Direct Comparison of B-Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP in a Large Population of Patients with Chronic and Symptomatic Heart Failure: The Valsartan Heart Failure (Val-HeFT) Data","volume":"52","author":"Masson","year":"2006","journal-title":"Clin. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.jacc.2018.01.021","article-title":"N-Terminal Pro\u2013B-Type Natriuretic Peptide in the Emergency Department","volume":"71","author":"Januzzi","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMoa031681","article-title":"Use of B-Type Natriuretic Peptide in the Evaluation and Management of Acute Dyspnea","volume":"350","author":"Mueller","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ejhf.1494","article-title":"Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations","volume":"21","author":"Mueller","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10654-009-9339-6","article-title":"N-terminal pro B-type natriuretic peptide as prognostic marker for mortality in coronary patients without clinically manifest heart failure","volume":"24","author":"Mayer","year":"2009","journal-title":"Eur. J. Epidemiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12265-020-10042-3","article-title":"The Role of Biomarkers in Cardio-Oncology","volume":"13","author":"Ananthan","year":"2020","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3389\/fphar.2020.00740","article-title":"Troponins and Natriuretic Peptides in Cardio-Oncology Patients\u2014Data From the ECoR Registry","volume":"11","author":"Hinrichs","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/ehf2.13735","article-title":"Novel molecular biomarkers of cancer therapy-induced cardiotoxicity in adult population: A scoping review","volume":"9","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/01.CIR.0000025242.79963.4C","article-title":"B-Type Natriuretic Peptide and Clinical Judgment in Emergency Diagnosis of Heart Failure","volume":"106","author":"McCullough","year":"2002","journal-title":"Circulation"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cardfail.2016.04.003","article-title":"The Utility of Point-of-Care Biomarkers to Detect Cardiotoxicity During Anthracycline Chemotherapy: A Feasibility Study","volume":"22","author":"Lenihan","year":"2016","journal-title":"J. Card. Fail."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000443505","article-title":"Limitations of N-Terminal Pro-B-Type Natriuretic Peptide in the Diagnosis of Heart Disease among Cancer Patients Who Present with Cardiac or Pulmonary Symptoms","volume":"90","author":"Wieshammer","year":"2016","journal-title":"Oncology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/mpo.1155","article-title":"Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer","volume":"37","author":"Hayakawa","year":"2001","journal-title":"Med. Pediatr. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1136\/heartjnl-2015-307848","article-title":"Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality","volume":"101","author":"Pavo","year":"2015","journal-title":"Heart"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejheart.2004.03.009","article-title":"Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction","volume":"7","author":"Daugaard","year":"2005","journal-title":"Eur. J. Heart Fail."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1007\/s13277-015-4183-7","article-title":"Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients","volume":"37","author":"Salerno","year":"2016","journal-title":"Tumor Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1200\/JCO.2015.65.7916","article-title":"Role of Troponins I and T and N -Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2\u2013Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study C","volume":"35","author":"Zardavas","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2147\/VHRM.S327661","article-title":"The Main Causes and Mechanisms of Increase in Cardiac Troponin Concentrations Other Than Acute Myocardial Infarction (Part 1): Physical Exertion, Inflammatory Heart Disease, Pulmonary Embolism, Renal Failure, Sepsis","volume":"17","author":"Chauin","year":"2021","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.lab.2005.02.003","article-title":"Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines","volume":"145","author":"Specchia","year":"2005","journal-title":"J. Lab. Clin. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/0004563216650464","article-title":"High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury","volume":"54","author":"Jones","year":"2017","journal-title":"Ann. Clin. Biochem. Int. J. Lab. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/CAD.0b013e328011335e","article-title":"Troponin-T and myoglobin plus echocardiographic evaluation for monitoring early cardiotoxicity of weekly epirubicin\u2013paclitaxel in metastatic breast cancer patients","volume":"18","author":"Bria","year":"2007","journal-title":"Anticancer Drugs"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/ejhf.2017","article-title":"Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: A position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Socie","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ejhf.1631","article-title":"Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: A meta-analysis","volume":"22","author":"Michel","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial","volume":"71","author":"Avila","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e006513","DOI":"10.1161\/JAHA.117.006513","article-title":"Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study","volume":"6","author":"Gulati","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): A 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"23","author":"Lyon","year":"2022","journal-title":"Eur. Hear. J.-Cardiovasc. Imaging"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2459\/JCM.0b013e3283590d59","article-title":"Copeptin","volume":"14","author":"Morawiec","year":"2013","journal-title":"J. Cardiovasc. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc990","article-title":"The endothelin axis: Emerging role in cancer","volume":"3","author":"Nelson","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"H1869","DOI":"10.1152\/ajpheart.1995.268.5.H1869","article-title":"ANP secretion from small cell lung cancer cell lines: A potential model of ANP release","volume":"268","author":"Wigle","year":"1995","journal-title":"Am. J. Physiol. Circ. Physiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000011957","article-title":"Human Small Cell Lung Cancer Cells Produce Brain Natriuretic Peptide","volume":"56","author":"Ohsaki","year":"1999","journal-title":"Oncology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/chf.12018","article-title":"What Is Causing Extremely Elevated Amino Terminal Brain Natriuretic Peptide in Cancer Patients?","volume":"19","author":"Popat","year":"2013","journal-title":"Congest. Heart Fail."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/01.coc.0000256101.04404.b0","article-title":"Cancer Patients With Markedly Elevated B-Type Natriuretic Peptide May Not Have Volume Overload","volume":"30","author":"Burjonroppa","year":"2007","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1749-8090-1-37","article-title":"Detected troponin elevation is associated with high early mortality after lung resection for cancer","volume":"1","author":"Lim","year":"2006","journal-title":"J. Cardiothorac. Surg."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.clinbiochem.2013.04.029","article-title":"Highly-sensitive troponin I is increased in patients with gynecological cancers","volume":"46","author":"Danese","year":"2013","journal-title":"Clin. Biochem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.cardiores.2006.08.018","article-title":"Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure","volume":"73","author":"Vonhaehling","year":"2007","journal-title":"Cardiovasc. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.pharmthera.2008.09.009","article-title":"Cardiac cachexia: A systematic overview","volume":"121","author":"Lainscak","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/eurheartj\/eht302","article-title":"Prevention of liver cancer cachexia-induced cardiac wasting and heart failure","volume":"35","author":"Springer","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/joim.13053","article-title":"Tumour biomarkers: Association with heart failure outcomes","volume":"288","author":"Shi","year":"2020","journal-title":"J. Intern. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.ejheart.2004.12.008","article-title":"Tumour marker levels in patients with chronic heart failure","volume":"7","author":"Varol","year":"2005","journal-title":"Eur. J. Heart Fail."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/eurjhf\/hfr022","article-title":"Tumour biomarkers in heart failure: Is there a role for CA-125?","volume":"13","author":"Yilmaz","year":"2011","journal-title":"Eur. J. Heart Fail."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2459\/01.JCM.0000237903.95882.06","article-title":"Tumour markers in chronic heart failure. Review of the literature and clinical implications","volume":"7","author":"Faggiano","year":"2006","journal-title":"J. Cardiovasc. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"7459","DOI":"10.2147\/OTT.S100510","article-title":"Biomarkers in pancreatic adenocarcinoma: Current perspectives","volume":"9","author":"Swords","year":"2016","journal-title":"OncoTargets Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ejheart.2005.09.002","article-title":"Relationship between cytokines and tumour markers in patients with chronic heart failure","volume":"8","author":"Kosar","year":"2006","journal-title":"Eur. J. Heart Fail."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/eurheartj\/ehac710","article-title":"Cancer is a comorbidity of heart failure","volume":"44","author":"Ameri","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/CIRCULATIONAHA.117.030816","article-title":"Heart failure stimulates tumor growth by circulating factors","volume":"138","author":"Meijers","year":"2018","journal-title":"Circulation"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1161\/CIRCULATIONAHA.118.033603","article-title":"Linking Heart Failure to Cancer","volume":"138","author":"Bertero","year":"2018","journal-title":"Circulation"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"112","DOI":"10.15420\/cfr.2018.32.2","article-title":"Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients","volume":"5","author":"Cuomo","year":"2019","journal-title":"Card. Fail. Rev."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11912-020-00990-z","article-title":"Cancer Risk in the Heart Failure Population: Epidemiology, Mechanisms, and Clinical Implications","volume":"23","author":"Cuomo","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11897-021-00517-y","article-title":"New-Onset Cancer in the HF Population: Epidemiology, Pathophysiology, and Clinical Management","volume":"18","author":"Cuomo","year":"2021","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ejhf.472","article-title":"Incidence of cancer in patients with chronic heart failure: A long-term follow-up study","volume":"18","author":"Banke","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/ejhf.531","article-title":"A systems BIOlogy Study to Tailored Treatment in Chronic Heart Failure: Rationale, design, and baseline characteristics of BIOSTAT-CHF","volume":"18","author":"Voors","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cyto.2018.07.037","article-title":"NT-proBNP and CA 125 levels are associated with increased pro-inflammatory cytokines in coronary sinus serum of patients with chronic heart failure","volume":"111","author":"Stanciu","year":"2018","journal-title":"Cytokine"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10741-013-9402-y","article-title":"Clinical utility of antigen carbohydrate 125 in heart failure","volume":"19","author":"Chorro","year":"2014","journal-title":"Heart Fail. Rev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e011044","DOI":"10.1136\/heartasia-2018-011044","article-title":"Cancer antigen-125 and outcomes in acute heart failure: A systematic review and meta-analysis","volume":"10","author":"Li","year":"2018","journal-title":"Heart Asia"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/j.clinbiochem.2013.09.008","article-title":"Elevation of carbohydrate antigen 125 in chronic heart failure may be caused by mechanical extension of mesothelial cells from serous cavity effusion","volume":"46","author":"Huang","year":"2013","journal-title":"Clin. Biochem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3904\/kjim.2017.313","article-title":"Serum levels of carbohydrate antigen 125 in combination with N-terminal pro-brain natriuretic peptide in patients with acute decompensated heart failure","volume":"34","author":"Yoon","year":"2019","journal-title":"Korean J. Intern. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cardfail.2016.05.002","article-title":"HE4 Serum Levels Are Associated with Heart Failure Severity in Patients With Chronic Heart Failure","volume":"23","author":"Piek","year":"2017","journal-title":"J. Card. Fail."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jchf.2012.11.005","article-title":"The WAP Four-Disulfide Core Domain Protein HE4: A Novel Biomarker for Heart Failure","volume":"1","author":"Cao","year":"2013","journal-title":"JACC Heart Fail."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/10408363.2018.1460576","article-title":"Novel heart failure biomarkers: Why do we fail to exploit their potential?","volume":"55","author":"Piek","year":"2018","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Mercurio, V., Cuomo, A., Dessalvi, C.C., Deidda, M., Di Lisi, D., Novo, G., Manganaro, R., Zito, C., Santoro, C., and Ameri, P. (2020). Redox imbalances in ageing and metabolic alterations: Implications in cancer and cardiac diseases. An overview from the working group of cardiotoxicity and cardioprotection of the Italian society of cardiology (SIC). Antioxidants, 9.","DOI":"10.3390\/antiox9070641"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1161\/01.RES.0000150734.79804.92","article-title":"Cytokine-Induced Modulation of Cardiac Function","volume":"95","author":"Prabhu","year":"2004","journal-title":"Circ. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/eurjhf\/hfr122","article-title":"The role of monocytes and inflammation in the pathophysiology of heart failure","volume":"13","author":"Wrigley","year":"2011","journal-title":"Eur. J. Heart Fail."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/S1470-2045(12)70582-X","article-title":"Cytokine patterns in patients with cancer: A systematic review","volume":"14","author":"Lippitz","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/jnci\/djr216","article-title":"Increased Levels of Circulating Interleukin 6, Interleukin 8, C-Reactive Protein, and Risk of Lung Cancer","volume":"103","author":"Pine","year":"2011","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"94","DOI":"10.14715\/cmb\/2018.64.6.16","article-title":"Levels of peripheral Th17 cells and serum Th17-related cytokines in patients with colorectal cancer: A meta-analysis","volume":"64","author":"Yan","year":"2018","journal-title":"Cell. Mol. Biol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.healun.2003.07.023","article-title":"Interleukin-6 and B-type natriuretic peptide are independent predictors for worsening of heart failure in patients with progressive congestive heart failure","volume":"23","author":"Gwechenberger","year":"2004","journal-title":"J. Heart Lung Transplant."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: A position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijcard.2021.11.059","article-title":"Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: The HFA\/ICOS risk tool in real-world practice","volume":"349","author":"Tini","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/ehf2.13897","article-title":"The new HFA\/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity","volume":"9","author":"Madaudo","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0735-1097(00)00748-8","article-title":"Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy","volume":"36","author":"Cardinale","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/14737159.2017.1283219","article-title":"Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy","volume":"17","author":"Cardinale","year":"2017","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e13400","DOI":"10.1111\/eci.13400","article-title":"Pre-treatment high-sensitivity troponin T for the short-term prediction of cardiac outcomes in patients on immune checkpoint inhibitors","volume":"51","author":"Petricciuolo","year":"2021","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/JXX.0000000000000927","article-title":"Elevated brain natriuretic peptide in a patient with metastatic cancer without heart failure: A case study","volume":"36","author":"Chen","year":"2023","journal-title":"J. Am. Assoc. Nurse Pract."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1161\/CIRCULATIONAHA.123.064274","article-title":"Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I\u2013Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial","volume":"148","author":"Henriksen","year":"2023","journal-title":"Circulation"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"omx038","DOI":"10.1093\/omcr\/omx038","article-title":"Long-term irreversible trastuzumab-induced cardiotoxicity for metastatic breast cancer in a patient without cardiac risk factors","volume":"2017","author":"Tanaka","year":"2017","journal-title":"Oxford Med. Case Rep."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Lunardi, M., Al-Habbaa, A., Abdelshafy, M., Davey, M.G., Elkoumy, A., Ganly, S., Elzomor, H., Cawley, C., Sharif, F., and Crowley, J. (2022). Genetic and RNA-related molecular markers of trastuzumab-chemotherapy-associated cardiotoxicity in HER2 positive breast cancer: A systematic review. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09437-z"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1093\/oncolo\/oyab035","article-title":"Cardiotoxicity from Capecitabine Chemotherapy: Prospective Study of Incidence at Rest and During Physical Exercise","volume":"27","author":"Lestuzzi","year":"2022","journal-title":"Oncologist"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","article-title":"Adverse effects of anticancer agents that target the VEGF pathway","volume":"6","author":"Chen","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1089\/ars.2019.7842","article-title":"What Is the Cardiac Impact of Chemotherapy and Subsequent Radiotherapy in Lymphoma Patients?","volume":"31","author":"Mercurio","year":"2019","journal-title":"Antioxid. Redox Signal."},{"key":"ref_96","unstructured":"EMA (2023, December 29). Medicines European Medicines Agency. Eur Med Agency Sci Med Heal. Available online: https:\/\/www.ema.europa.eu\/en\/homepage."},{"key":"ref_97","unstructured":"FDA (2023, December 29). Drugs@FDA FDA-Approved Drugs, Available online: https:\/\/www.fda.gov\/drugs."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00204-018-2356-z","article-title":"MicroRNAs in the diagnosis and prevention of drug-induced cardiotoxicity","volume":"93","year":"2019","journal-title":"Arch. Toxicol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/cvr\/cvq148","article-title":"Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway","volume":"87","author":"Horie","year":"2010","journal-title":"Cardiovasc. Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in Patients Treated With Immune Checkpoint Inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10549-012-2039-z","article-title":"High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: A pilot study","volume":"134","author":"Onitilo","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"22","DOI":"10.18087\/cardio.2023.4.n1946","article-title":"Anthra cycline-Induced Cardiotoxicity: The Role of Genetic Predictors","volume":"63","author":"Kopeva","year":"2023","journal-title":"Kardiologiia"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/FPC.0000000000000284","article-title":"Genome-wide association and pathway analysis of left ventricular function after anthracycline exposure in adults","volume":"27","author":"Wells","year":"2017","journal-title":"Pharmacogenet. Genom."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/CIRCULATIONAHA.121.055801","article-title":"Identification of Drug Transporter Genomic Variants and Inhibitors That Protect Against Doxorubicin-Induced Cardiotoxicity","volume":"145","author":"Magdy","year":"2022","journal-title":"Circulation"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/cas.13471","article-title":"Whole exome sequencing to identify genetic markers for trastuzumab-induced cardiotoxicity","volume":"109","author":"Udagawa","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1365-2125.2010.03896.x","article-title":"Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients","volume":"71","author":"Formento","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jacc.2007.04.074","article-title":"Polymorphisms of KDRGene Are Associated With Coronary Heart Disease","volume":"50","author":"Wang","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/S1470-2045(14)70409-7","article-title":"Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: A report from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"16","author":"Armenian","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijcard.2009.09.564","article-title":"Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: Effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide","volume":"148","author":"Feola","year":"2011","journal-title":"Int. J. Cardiol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e014708","DOI":"10.1161\/JAHA.119.014708","article-title":"Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction","volume":"9","author":"Demissei","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/eurheartj\/ehaa006","article-title":"Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: The CARDIOTOX registry","volume":"41","author":"Lyon","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jaccao.2020.10.011","article-title":"Strain Imaging in Cardio-Oncology","volume":"2","author":"Liu","year":"2020","journal-title":"JACC Cardio Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"102.e1","DOI":"10.1016\/j.ahj.2008.08.032","article-title":"Use of myocardial strain to assess global left ventricular function: A comparison with cardiac magnetic resonance and 3-dimensional echocardiography","volume":"157","author":"Brown","year":"2009","journal-title":"Am. Heart J."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cjca.2017.11.018","article-title":"Left Ventricular Strain in Chemotherapy-Naive and Radiotherapy-Naive Patients With Cancer","volume":"34","author":"Tadic","year":"2018","journal-title":"Can. J. Cardiol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s10741-023-10332-3","article-title":"Advance of echocardiography in cardiac amyloidosis","volume":"28","author":"Liang","year":"2023","journal-title":"Heart Fail. Rev."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"782580","DOI":"10.3389\/fcvm.2021.782580","article-title":"Myocardial Injury in Multiple Myeloma Patients With Preserved Left Ventricular Ejection Fraction: Noninvasive Left Ventricular Pressure-Strain Myocardial Work","volume":"8","author":"Liu","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Alexandraki, A., Papageorgiou, E., Zacharia, M., Keramida, K., Papakonstantinou, A., Cipolla, C.M., Tsekoura, D., Naka, K., Mazzocco, K., and Mauri, D. (2023). New Insights in the Era of Clinical Biomarkers as Potential Predictors of Systemic Therapy-Induced Cardiotoxicity in Women with Breast Cancer: A Systematic Review. Cancers, 15.","DOI":"10.3390\/cancers15133290"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1093\/cvr\/cvaa222","article-title":"Cardiac dysfunction in cancer patients: Beyond direct cardiomyocyte damage of anticancer drugs: Novel cardio-oncology insights from the joint 2019 meeting of the ESC working groups of myocardial function and cellular biology of the heart","volume":"116","author":"Tocchetti","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1101\/gr.082701.108","article-title":"Most mammalian mRNAs are conserved targets of microRNAs","volume":"19","author":"Friedman","year":"2009","journal-title":"Genome Res."},{"key":"ref_124","first-page":"1589","article-title":"A systematic review of miRNAs as biomarkers for chemotherapy-induced cardiotoxicity in breast cancer patients reveals potentially clinically informative panels as well as key challenges in miRNA research","volume":"81","author":"Brown","year":"2022","journal-title":"Cardio-Oncology"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"7954","DOI":"10.1038\/s41598-021-87209-8","article-title":"Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer","volume":"11","author":"Lakhani","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1373\/clinchem.2015.241232","article-title":"Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab","volume":"61","author":"Putt","year":"2015","journal-title":"Clin. Chem."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1161\/01.CIR.0000147181.65298.4D","article-title":"Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction","volume":"110","author":"Sharma","year":"2004","journal-title":"Circulation"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3109\/1354750X.2015.1040839","article-title":"New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide","volume":"20","author":"Bulten","year":"2015","journal-title":"Biomarkers"},{"key":"ref_129","first-page":"706","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"69","author":"Seidman","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.31557\/APJCP.2021.22.10.3355","article-title":"Serum Biomarkers for Chemotherapy Cardiotoxicity Risk Detection of Breast Cancer Patients","volume":"22","author":"Hasan","year":"2021","journal-title":"Asian Pacific. J. Cancer Prev."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/1120009X.2021.1873632","article-title":"Proinflammatory circulating markers: New players for evaluating asymptomatic acute cardiovascular toxicity in breast cancer treatment","volume":"33","author":"Micheletti","year":"2021","journal-title":"J. Chemother."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early Increases in Multiple Biomarkers Predict Subsequent Cardiotoxicity in Patients With Breast Cancer Treated With Doxorubicin, Taxanes, and Trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00424-020-02459-1","article-title":"GDF15, an update of the physiological and pathological roles it plays: A review","volume":"472","author":"Assadi","year":"2020","journal-title":"Pfl\u00fcgers Arch.-Eur. J. Physiol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/ehjcvp\/pvab016","article-title":"Cardiac and cardiometabolic phenotyping of trastuzumab-mediated cardiotoxicity: A secondary analysis of the MANTICORE trial","volume":"8","author":"Kirkham","year":"2022","journal-title":"Eur. Heart J.-Cardiovasc. Pharmacother."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/ejhf.1758","article-title":"Long-term survivors of early breast cancer treated with chemotherapy are characterized by a pro-inflammatory biomarker profile compared to matched controls","volume":"22","author":"Tromp","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"821162","DOI":"10.3389\/fcvm.2022.821162","article-title":"RNA Virus Gene Signatures Detected in Patients With Cardiomyopathy After Chemotherapy; A Pilot Study","volume":"9","author":"Varkoly","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Deidda, M., Mercurio, V., Cuomo, A., Noto, A., Mercuro, G., and Cadeddu Dessalvi, C. (2019). Metabolomic Perspectives in Antiblastic Cardiotoxicity and Cardioprotection. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20194928"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/toxsci\/kfaa015","article-title":"A Targeted Metabolomics-Based Assay Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Identifies Structural and Functional Cardiotoxicity Potential","volume":"174","author":"Palmer","year":"2020","journal-title":"Toxicol. Sci."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00204-021-03204-y","article-title":"Cardiotoxicity of cyclophosphamide\u2019s metabolites: An in vitro metabolomics approach in AC16 human cardiomyocytes","volume":"96","author":"Bastos","year":"2022","journal-title":"Arch. Toxicol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1021\/pr501116c","article-title":"Screening, Verification, and Optimization of Biomarkers for Early Prediction of Cardiotoxicity Based on Metabolomics","volume":"14","author":"Li","year":"2015","journal-title":"J. Proteome Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/jat.3307","article-title":"Early metabolomics changes in heart and plasma during chronic doxorubicin treatment in B6C3F 1 mice","volume":"36","author":"Schnackenberg","year":"2016","journal-title":"J. Appl. Toxicol."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Tan, G., Lou, Z., Liao, W., Zhu, Z., Dong, X., Zhang, W., Li, W., and Chai, Y. (2011). Potential Biomarkers in Mouse Myocardium of Doxorubicin-Induced Cardiomyopathy: A Metabonomic Method and Its Application. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0027683"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Jensen, B., Parry, T., Huang, W., Ilaiwy, A., Bain, J., Muehlbauer, M., O\u2019Neal, S., Patterson, C., Johnson, G., and Willis, M. (2017). Non-Targeted Metabolomics Analysis of the Effects of Tyrosine Kinase Inhibitors Sunitinib and Erlotinib on Heart, Muscle, Liver and Serum Metabolism In Vivo. Metabolites, 7.","DOI":"10.3390\/metabo7030031"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1111\/bph.14062","article-title":"Effects of the kinase inhibitor sorafenib on heart, muscle, liver and plasma metabolism in vivo using non-targeted metabolomics analysis","volume":"174","author":"Jensen","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.radonc.2020.04.018","article-title":"Plasma metabolite biomarkers predictive of radiation induced cardiotoxicity","volume":"152","author":"Unger","year":"2020","journal-title":"Radiother. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s12265-019-09897-y","article-title":"Changes in Citric Acid Cycle and Nucleoside Metabolism Are Associated with Anthracycline Cardiotoxicity in Patients with Breast Cancer","volume":"13","author":"Asnani","year":"2020","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"ehaa946.3289","DOI":"10.1093\/ehjci\/ehaa946.3289","article-title":"Defining the metabolomic profile associated with early cardiotoxicity in patients with breast cancer treated with anthracyclines","volume":"41","author":"Cocco","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"645122","DOI":"10.3389\/fcvm.2021.645122","article-title":"Lactate Dehydrogenase B and Pyruvate Oxidation Pathway Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: Result of a Multi-Omics Integrative Analysis","volume":"8","author":"Tantawy","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"8774971","DOI":"10.1155\/2023\/8774971","article-title":"The Regulation Network of Glycerolipid Metabolism as Coregulators of Immunotherapy-Related Myocarditis","volume":"2023","author":"Yang","year":"2023","journal-title":"Cardiovasc. Ther."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/2\/199\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:56:23Z","timestamp":1760104583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/2\/199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":149,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["biom14020199"],"URL":"https:\/\/doi.org\/10.3390\/biom14020199","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,7]]}}}